Method of enhancing the biological activity of ligands
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSamuel Davis, Nicholas W. Gale, George D. Yancopoulos, Neil Stahl
Life of this patent
Estimating the term…
Abstract
Novel fusion polypeptide ligands that bind Eph family receptors or the Tie-2 receptor are identified, and methods for making the fusion polypeptide ligands in biologically active form are described. Nucleic acids encoding these novel fusion polypeptide ligands enable production of the fusion polypeptide ligands. The method of making the nucleic acids and the fusion polypeptide ligands is broadly applicable to the production of polypeptide ligands in general, resulting in improved affinity and/or increased activity of the ligand when compared to its native form.
Claims15
An isolated nucleic acid molecule encoding a fusion polypeptide, wherein the fusion polypeptide consists of a first subunit comprising a receptor binding domain of angiopoietin-1, fused to an N-terminal end of a multimerizing component, and the multimerizing component fused at its C-terminal end to a second receptor binding domain of angiopoietin-1, wherein the multimerizing component is an immunoglobulin derived domain selected from the group consisting of the Fc domain of IgG and the heavy chain of IgG.
Dependencies are inferred from the claim text.